Clinical next generation sequencing to identify actionable aberrations in a phase I program

Oncotarget

Volumn 6, Issue 24, 2015, Pages 20099-20110

  Boland, Genevieve M ^a,b   Piha Paul, Sarina A ^b   Subbiah, Vivek ^b   Routbort, Mark ^b   Herbrich, Shelley M ^b   Baggerly, Keith ^b   Patel, Keyur P ^b   Brusco, Lauren ^b   Horombe, Chacha ^b   Naing, Aung ^b   Fu, Siqing ^b   Hong, David S ^b   Janku, Filip ^b   Johnson, Amber ^b   Broaddus, Russell ^b   Luthra, Raja ^b   Shaw, Kenna ^b   Mendelsohn, John ^b   Mills, Gordon B ^b   Meric Bernstam, Funda ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Actionable genes; Genomic sequencing

Indexed keywords

ATM PROTEIN; DNA; PROTEIN P53; SCATTER FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CLASSIFICATION; CANCER INCIDENCE; CARCINOGENESIS; CELL LINEAGE; CLINICAL PROTOCOL; COLORECTAL CANCER; COLORECTAL TUMOR; CONTROLLED STUDY; DNA SEQUENCE; ENDOMETRIUM CANCER; ENDOMETRIUM TUMOR; ESOPHAGUS TUMOR; GENE EXPRESSION PROFILING; GENE MUTATION; GENE TARGETING; GENETIC VARIABILITY; GENOTYPE; HEAD AND NECK TUMOR; HUMAN; HUMAN TISSUE; KIDNEY CANCER; KIDNEY TUMOR; LIVER TUMOR; LUNG TUMOR; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; METASTASIS POTENTIAL; NEUROENDOCRINE TUMOR; ONCOGENE; ONCOGENE APC; ONCOGENE ATM; ONCOGENE BRAF; ONCOGENE FBXW7; ONCOGENE HRAS; ONCOGENE K RAS; ONCOGENE KDR; ONCOGENE KIT; ONCOGENE MET; ONCOGENE PIK3CA; ONCOGENE SMAD4; ONCOGENE TP53; OVARY TUMOR; PANCREAS CANCER; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL; PROSPECTIVE STUDY; PROSTATE TUMOR; SARCOMA; SOMATIC MUTATION; STOMACH TUMOR; THYROID TUMOR; CLINICAL TRIAL; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; NEOPLASM; PERSONALIZED MEDICINE; PROCEDURES;

HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; NEOPLASMS; PRECISION MEDICINE;

EID: 84940172694     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4040     Document Type: Article

References (22)

1. The Cancer Genome Atlas, The National Cancer Institute at NIH. http://cancergenome.nih.gov/. Accessed 10/10/2014, 2014.
2. International Cancer Genome C, Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, et al. International network of cancer genome projects. Nature. 2010; 464:993-998.
3. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011; 3:111ra121.
4. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME and King CR. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990; 8:103-112.
5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364:2507-2516.
6. Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, Kanagal-Shamanna R, Greaves WO, Medeiros LJ, Aldape KD and Luthra R. Clinical validation of a next generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013; 15:607-622.
7. Singh RR, Patel KP, Routbort MJ, Aldape K, Lu X, Manekia J, Abraham R, Reddy NG, Barkoh BA, Veliyathu J, Medeiros LJ and Luthra R. Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. British journal of cancer. 2014; 111:2014-2023.
8. Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, et al. Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. Clinical Chem. 2015; 61:544-553.
9. Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, et al. A Decision Support Framework for Genomically Informed Investigational Cancer Therapy. JNCI. 2015; 107.
10. Bertheau P, Turpin E, Rickman DS, Espie M, de Reynies A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A and de The H. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med. 2007; 4:e90.
11. Cortinovis DL, Andriani F, Livio A, Fabbri A, Perrone F, Marcomini B, Pilotti S, Mariani L, Bidoli P, Bajetta E, Roz L and Sozzi G. FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer. Curr Cancer Drug Targets. 2008; 8:342-348.
12. Hoff PM. Is there a role for routine p53 testing in colorectal cancer? J Clin Oncol. 2005; 23:7395-7396.
13. Munro AJ, Lain S and Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005; 92:434-444.
14. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T and Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005; 23:7518-7528.
15. Oden-Gangloff A, Di Fiore F, Bibeau F, Lamy A, Bougeard G, Charbonnier F, Blanchard F, Tougeron D, Ychou M, Boissiere F, Le Pessot F, Sabourin JC, Tuech JJ, Michel P and Frebourg T. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br J Cancer. 2009; 100:1330-1335.
16. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F and Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006; 66:3992-3995.
17. Goldman JW and Garon EB. Targeting MEK for the treatment of non-small-cell lung cancer. J Thorac Oncol. 2012; 7:S377-378.
18. Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, Smith I and Crino L. Selumetinib plus docetaxel for KRASmutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013; 14:38-47.
19. Eser S, Schnieke A, Schneider G and Saur D. Oncogenic KRAS signalling in pancreatic cancer. Bri J Cancer. 2014; 111:817-822.
20. Camidge DR, Pao W and Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014; 11:473-481.
21. Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Perez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, et al. Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther. 2014; 13:1382-1389.
22. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gomez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014; 20:1757-1767.